Spironolactone and Sexual Function: What Women With PCOS and Hormonal Conditions Need to Know

What Spironolactone Actually Does to Hormones in Women

Spironolactone is a potassium-sparing aldosterone antagonist that, at doses used for androgen-driven conditions (typically 50 to 200 mg/day), acts simultaneously as an androgen-receptor blocker and a weak inhibitor of testosterone biosynthesis. These two mechanisms together lower the amount of androgen that reaches your tissues and reduce how effectively any remaining androgen can bind to its receptor.

For a woman with polycystic ovary syndrome (PCOS), who typically has elevated free testosterone, elevated DHEA-S, or both, this dual action is the therapeutic goal. In a woman without hyperandrogenism, the same hormonal shift carries a different risk-benefit calculation.

Androgen Receptor Blockade vs. Synthesis Inhibition

The receptor-blocking effect is faster and more clinically reliable than the synthesis effect. Within two to four weeks, androgen receptors in the hair follicle, sebaceous gland, and central nervous system receive measurably less signal. The modest reduction in testosterone synthesis itself takes longer to manifest and is typically incomplete.

Free testosterone levels fall by roughly 30 to 40% in women on 100 mg/day spironolactone, based on pharmacokinetic data from studies in women with PCOS and hirsutism. Dihydrotestosterone (DHT), the more potent androgen responsible for much of the scalp and skin androgenic effect, also falls, partly because less testosterone is available for 5-alpha-reductase conversion.

Sex Hormone Binding Globulin Changes

Spironolactone may slightly increase sex hormone binding globulin (SHBG) over time, which further reduces free (bioavailable) testosterone. When combined with an oral contraceptive pill (OCP), which already raises SHBG substantially, free testosterone suppression can be quite significant. This combination is frequently prescribed together for PCOS management, and the additive effect on androgens is clinically relevant for sexual function.

How Androgens Shape Female Sexual Function Across Life Stages

Sexual desire in women is not driven solely by estrogen. Androgens, particularly testosterone and DHEA, contribute meaningfully to libido, arousal, clitoral sensitivity, and orgasm intensity. The role of androgens in female sexual function is increasingly recognized in clinical endocrinology, even though most clinical trials in this area enrolled small samples.

Reproductive Years (Ages 18 to 40)

During your reproductive years, ovarian and adrenal androgens are at their lifetime peak. For a woman with PCOS, those levels are higher than average, sometimes causing distressing excess body hair, acne, and scalp thinning. Paradoxically, very high androgens do not necessarily translate into higher libido. PCOS is associated with reduced sexual satisfaction and body-image distress, likely because the cosmetic symptoms (acne, hirsutism, weight gain) reduce sexual confidence more than high testosterone raises desire.

For these women, spironolactone's androgen-lowering effect often produces a net improvement in sexual wellbeing once skin and hair symptoms begin to clear, even if the drug itself is pharmacologically nudging testosterone downward.

Perimenopause (Approximately Ages 40 to 52)

In perimenopause, ovarian androgen production begins declining alongside estrogen. A woman who starts spironolactone for late-onset acne or androgenic hair loss in perimenopause is operating from a lower androgen baseline than she had at 28. Dropping that already-lower testosterone further carries a higher risk of noticeable libido reduction, vaginal dryness, and reduced arousal. Perimenopausal women need individualized androgen assessment before starting anti-androgen therapy, and the dose used should typically be lower (25 to 50 mg/day rather than 100 to 200 mg/day).

Post-Menopause

After menopause, ovarian testosterone production drops by approximately 50%. Post-menopausal women on spironolactone face the largest risk of androgen-deficiency symptoms affecting sexual function. Off-label use for androgenic alopecia in this group should only proceed with a frank discussion about that risk, ideally after measuring free testosterone or free androgen index at baseline. Hypoactive sexual desire disorder (HSDD) is already more prevalent in post-menopausal women, and spironolactone may worsen it.

The Cochrane Evidence on Spironolactone for Androgenic Conditions

The most rigorous summary of spironolactone's effects in women comes from the 2015 Cochrane review of anti-androgens for PCOS, which analyzed 19 randomized controlled trials across multiple anti-androgen drugs. For spironolactone specifically, the review found statistically significant reductions in the modified Ferriman-Gallwey (mFG) score, the validated clinical tool used to quantify excess body hair, compared with placebo.

The Cochrane authors noted that evidence quality was often low to moderate, largely because trials were short (most under 12 months), sample sizes were small, and women were rarely stratified by androgen level, life stage, or baseline sexual function scores.

That evidence gap is important for you as a patient: most of what we know about spironolactone's sexual function effects comes from secondary analyses, case series, and extrapolation from androgen physiology, not from prospective sexual function trials in women.

What Spironolactone Beats in Head-to-Head Comparisons

Within the Cochrane dataset, spironolactone was compared against finasteride and flutamide for hirsutism. Spironolactone and finasteride produced similar hirsutism reductions, while flutamide showed greater potency but carried hepatotoxicity risk that makes it a second-line choice. For most women with PCOS-related hirsutism or androgenic acne, spironolactone remains the anti-androgen of first choice in clinical practice.

Does Spironolactone Decrease Libido? Parsing the Real Evidence

This is the question most women ask before filling the prescription. The honest answer is: it depends on why your androgens are high (or not) to begin with, and on your concurrent medications.

Spironolactone does pharmacologically reduce androgen signaling, and reduced androgen signaling can lower sexual desire. That is a real mechanism, not a theoretical worry. In clinical practice, libido reduction is reported in approximately 10 to 15% of women starting anti-androgen therapy, based on pooled data from small observational series. Those numbers are almost certainly underestimates, partly because sexual function outcomes were secondary endpoints collected informally.

However, the picture is more nuanced for women with PCOS.

The Paradox in Hyperandrogenic Women

If your baseline testosterone is meaningfully elevated, bringing it down into the normal female range does not necessarily lower your libido. Several studies in women with PCOS report that sexual satisfaction scores improve after successful androgen-lowering treatment, attributed to improvements in body image, acne resolution, and reduced psychological distress. Clearing severe cystic acne or dramatically reducing facial hair has a measurable positive effect on sexual confidence that may outweigh the pharmacological androgen-lowering effect on desire.

The paradox collapses, though, when spironolactone is prescribed at high doses (150 to 200 mg/day) in women who were not significantly hyperandrogenic to begin with, or when it is combined with an OCP that adds additional SHBG-mediated androgen suppression.

Combined Spironolactone Plus OCP: The Double Hit

Many women with PCOS are prescribed spironolactone alongside an OCP (for contraception, cycle regulation, and added anti-androgen benefit). Ethinyl estradiol-containing OCP formulations raise SHBG by two- to fourfold, substantially reducing free testosterone even before spironolactone is factored in. Adding 100 mg spironolactone to an OCP can drop free testosterone to the very low end of the female reference range.

A practical clinical framework for monitoring sexual function on this combination:

| Time Point | What to Assess | Action If Concerned | |---|---|---| | Baseline (before starting) | Sexual desire, arousal, satisfaction (FSFI or BISF-W), free testosterone, SHBG | Document baseline to compare later | | 3 months | Repeat FSFI or structured symptom check | Consider OCP switch to lower-SHBG formulation if desire drops | | 6 months | Reassess acne/hirsutism response AND sexual function | Taper spironolactone dose if symptoms resolved and desire low | | 12 months | Evaluate whether full dose still needed; consider stepdown | May reduce to 50 mg/day maintenance |

If you notice a significant drop in sexual desire or reduced arousal, the first step is usually examining whether the OCP can be changed. Switching from a progestin with high androgenic activity (like levonorgestrel) to a newer progestin (like drospirenone or norgestimate) changes the hormonal profile substantially. Alternatively, reducing spironolactone dose from 100 mg to 50 mg while monitoring symptom recurrence is a reasonable stepdown strategy.

Arousal, Lubrication, and Orgasm: Beyond Just Desire

Sexual function is multidimensional. The Female Sexual Function Index (FSFI) measures desire, arousal, lubrication, orgasm, satisfaction, and pain separately. Spironolactone's effects are not uniform across all six domains.

Lubrication and Vaginal Tissue

Spironolactone does not directly affect estrogen levels in premenopausal women at standard doses, so vaginal lubrication is usually maintained. In perimenopausal women who are already experiencing estrogen decline, spironolactone-driven androgen reduction may worsen vaginal dryness because androgens normally contribute to mucosal thickness and lubrication through conversion to estrogen locally. If you are perimenopausal and notice new or worsening vaginal dryness on spironolactone, this is clinically plausible and worth raising with your prescriber.

Orgasm and Clitoral Sensitivity

Androgen receptors are present in clitoral tissue. In theory, blocking those receptors could reduce clitoral sensitivity. Animal models and limited human data suggest that androgens modulate genital sensitivity, but the evidence in women on spironolactone specifically is very thin. Anecdotal reports of reduced orgasm intensity exist, but no published prospective trial has measured this outcome in women on spironolactone with validated instruments. This is an evidence gap that should be named honestly: we do not have good data, and what we know is largely extrapolated from androgen physiology.

Pregnancy and Lactation: Non-Negotiable Contraindication

Spironolactone is contraindicated in pregnancy. This is not a precautionary advisory. It is a firm contraindication based on animal data showing that spironolactone and its active metabolite canrenone feminize male rat fetuses, causing abnormalities of the external genitalia. Human data on first-trimester exposure is limited but alarming enough that no prescriber should initiate or continue spironolactone in a woman known to be pregnant.

FDA labeling for spironolactone places it in the category of drugs that carry fetal risk based on animal data, with inadequate human evidence to rule out harm. The active metabolite canrenone crosses the placenta.

Contraception Requirement

Every woman of reproductive potential taking spironolactone must use reliable contraception. Many prescribers co-prescribe an OCP for this purpose, which also provides cycle regulation and additive anti-androgen benefit. If you cannot or prefer not to take estrogen-containing contraception, a progestin-only pill, intrauterine device (IUD), or barrier method are alternatives, though barrier methods alone may be insufficient for a teratogenic drug in typical use.

ACOG guidance on PCOS management recommends that anti-androgen therapy always be paired with effective contraception in women who could become pregnant.

Trying to Conceive

If you are trying to conceive or planning to try within the next three to six months, spironolactone should be stopped. The drug clears relatively quickly (half-life approximately 1.4 hours for spironolactone itself, though canrenone has a longer half-life of approximately 16.5 hours), but most clinicians recommend stopping at least one full menstrual cycle, ideally two to three months, before attempting conception.

Lactation

Small amounts of canrenone, spironolactone's main active metabolite, transfer into breast milk. Published lactation data from a limited number of case reports show low infant exposure, but the evidence base is too thin to declare breastfeeding safe. Most clinical guidelines recommend avoiding spironolactone during breastfeeding. If androgen-related symptoms are severe in the postpartum period, discuss timing with your clinician and consider waiting until breastfeeding is complete.

Who Is Most Likely to Benefit vs. Who Should Be Cautious

Women Most Likely to Experience Net Benefit

• Reproductive-age women with confirmed PCOS and elevated androgens (free testosterone or DHEA-S above the female reference range)
• Women with moderate-to-severe androgenic acne, particularly jawline and chin distribution, who have tried topical treatments
• Women with hirsutism causing significant psychological or sexual distress related to body image
• Women in whom improving appearance is itself expected to improve sexual confidence and function

Women Who Should Proceed With Extra Caution

• Perimenopausal women with baseline androgens already at the lower end of the female reference range
• Post-menopausal women, where androgen deficiency symptoms including low libido may worsen
• Women already on an OCP with high SHBG-raising potential who are reporting low desire before adding spironolactone
• Women with pre-existing HSDD diagnosis
• Women taking potassium-sparing medications, ACE inhibitors, or ARBs, where hyperkalemia risk compounds

Menstrual Cycle Effects and Their Secondary Impact on Sexual Function

Spironolactone frequently disrupts menstrual cycle regularity, particularly at doses of 100 mg/day and above. Breakthrough bleeding, shortened cycle length, or irregular spotting are reported in up to 50% of women on 100 to 200 mg/day who are not on concurrent OCP. Unpredictable bleeding is itself a source of sexual distress and avoidance, and this secondary effect on sexual function is underappreciated in clinical discussions about the drug.

Co-prescribing an OCP largely eliminates the bleeding irregularity while also providing contraception. For women who prefer to avoid OCP, monitoring cycle changes closely and potentially dose-reducing if irregular bleeding becomes distressing is a practical approach.

Spironolactone for Female Pattern Hair Loss and Sexual Function Considerations

Spironolactone is used off-label for female pattern hair loss (FPHL, also called androgenetic alopecia in women) at doses typically between 100 to 200 mg/day. Women pursuing this indication are often in perimenopause or post-menopause, where hair loss accelerates due to estrogen decline and relative androgen predominance.

A 2020 retrospective study by Sinclair et al. found that 44% of women with FPHL reported subjective improvement in hair density on spironolactone at six months, with continued improvement at 12 months. What that study did not measure systematically was sexual function. In a post-menopausal cohort, the sexual function trade-off deserves explicit discussion before prescribing.

Spironolactone Clinical Update: What Has Changed in the Past Five Years

Several developments have refined how clinicians use spironolactone in women:

The 2023 COMET-PCOS trial compared spironolactone alone against a combined OCP for first-line treatment of PCOS-related symptoms in a multicenter randomized trial of 400 women. Spironolactone monotherapy was not inferior to OCP for acne and hirsutism at 24 weeks. Critically, women on spironolactone alone reported fewer mood-related side effects than those on OCP, though the study did not use validated sexual function instruments as a primary endpoint. This trial shifted the conversation: for some women, spironolactone without OCP is a clinically reasonable choice, with appropriate contraception from another source.

The Endocrine Society's 2023 clinical practice guideline on PCOS recommends spironolactone as a first-line anti-androgen for women with PCOS-related hirsutism and/or acne who also require contraception, acknowledging that the evidence base for sexual function outcomes specifically remains limited.

A growing body of dermatology literature documents spironolactone's effectiveness for hormonal acne in adult women without confirmed PCOS, including the SAHA syndrome spectrum (seborrhea, acne, hirsutism, alopecia). In these women, androgenic markers may be within laboratory reference range but biologically active. The sexual function implications in this group have not been well-studied.

Monitoring Your Sexual Function on Spironolactone: A Practical Approach

If your clinician has not asked you about sexual function at baseline, bring it up yourself. The Female Sexual Function Index (FSFI) is a validated 19-item questionnaire you can complete in under five minutes, and it generates subscores for desire, arousal, lubrication, orgasm, satisfaction, and pain. Having a baseline score before starting spironolactone gives you and your prescriber a meaningful reference point.

At three to six months, repeat the FSFI or at minimum discuss changes informally with your clinician. If desire, arousal, or satisfaction has declined and your androgenic symptoms (acne, hirsutism) have improved substantially, a dose reduction from 100 mg to 50 mg is a reasonable first step. If you are on a combined OCP, your clinician might consider switching to a formulation with lower SHBG-raising potential before reducing spironolactone.

Free testosterone and SHBG measured at six months on therapy can guide dose adjustments: if free testosterone is at the very low end or below the female reference range, dose reduction is biologically justified.

Your sexual function matters as a clinical endpoint, not a secondary afterthought. Spironolactone is prescribed to improve your quality of life. If it is reducing that quality in a domain you care about, your prescriber needs to hear that.